ReviewMolecules (Basel, Switzerland)2012
Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies.
Review in Molecules (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Proanthocyanidins inhibit CYP1B1 through mixed-type kinetics and stable binding in molecular dynamics simulations.Scientific reports · 2025Article
- Molecular Docking Study and 3D-QSAR Model for Trans-Stilbene Derivatives as Ligands of CYP1B1.International journal of molecular sciences · 2025Article
- QSPRmodeler - An open source application for molecular predictive analytics.Frontiers in bioinformatics · 2024Article
- Novel (Q)SAR models for prediction of reversible and time-dependent inhibition of cytochrome P450 enzymes.Frontiers in pharmacology · 2024Article
- Evaluation of the Usefulness of Topological Indices for Predicting Selected Physicochemical Properties of Bioactive Substances with Anti-Androgenic and Hypouricemic Activity.Molecules (Basel, Switzerland) · 2023Article
- Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform.Frontiers in pharmacology · 2022Article
- Coumarins and P450s, Studies Reported to-Date.Molecules (Basel, Switzerland) · 2019Review
- Ethyl 2-[2-(4-oxo-4IUCrData · 2018Article
- The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes.European journal of drug metabolism and pharmacokinetics · 2017Article
- Comprehensive and Automated Linear Interaction Energy Based Binding-Affinity Prediction for Multifarious Cytochrome P450 Aromatase Inhibitors.Journal of chemical information and modeling · 2017Article
- Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date.Molecules (Basel, Switzerland) · 2017Review
- Inhibition of Carcinogen-Activating Cytochrome P450 Enzymes by Xenobiotic Chemicals in Relation to Antimutagenicity and Anticarcinogenicity.Toxicological research · 2017Review
- Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.Current drug metabolism · 2017Review
- Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children.Drug metabolism and disposition: the biological fate of chemicals · 2016Article
- Linear Interaction Energy Based Prediction of Cytochrome P450 1A2 Binding Affinities with Reliability Estimation.PloS one · 2015Article
- Interactions between CYP3A4 and Dietary Polyphenols.Oxidative medicine and cellular longevity · 2015Review
- Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes.Frontiers in pharmacology · 2015Review
- Functional characterization of cytochromes P450 2B from the desert woodrat Neotoma lepida.Toxicology and applied pharmacology · 2014Article
- A Comparison of the In Vitro Inhibitory Effects of Thelephoric Acid and SKF-525A on Human Cytochrome P450 Activity.Biomolecules & therapeutics · 2014Article
- Pharmacological potential of biogenic amine-polyamine interactions beyond neurotransmission.British journal of pharmacology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The cytochrome P450 (CYP) superfamily of heme enzymes play an important role in the metabolism of a large number of endogenous and exogenous compounds, including most of the drugs currently on the market. Inhibitors of CYP enzymes have important roles in the treatment of several disease conditions such as numerous cancers and fungal infections in addition to their critical role in drug-drug interactions. Structure activity relationships (SAR), and three-dimensional quantitative structure activity relationships (3D-QSAR) represent important tools in understanding the interactions of the inhibitors with the active sites of the CYP enzymes. A comprehensive account of the QSAR studies on the major human CYPs 1A1, 1A2, 1B1, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, 3A4 and a few other CYPs are detailed in this review which will provide us with an insight into the individual/common characteristics of the active sites of these enzymes and the enzyme-inhibitor interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.